Scarica l'app Stockscreener
17.59
5.96%
0.99
Dopo l'orario di chiusura:
17.59
Bicara Therapeutics Inc Borsa (BCAX) Ultime notizie
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap DownShould You Sell? - MarketBeat
This cancer drug developer held the Bay State's largest IPO of 2024 - The Business Journals
Bicara Therapeutics (NASDAQ:BCAX) Reaches New 12-Month LowShould You Sell? - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 5.8%Time to Sell? - MarketBeat
The Manufacturers Life Insurance Company Takes $582,000 Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Sets New 1-Year LowShould You Sell? - MarketBeat
763,943 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Bought by Wellington Management Group LLP - MarketBeat
BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Point72 Asset Management L.P. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Now Covered by HC Wainwright - MarketBeat
Janus Henderson Group PLC Buys New Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
31,780 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Bought by Walleye Capital LLC - MarketBeat
2,273,792 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Bought by Fmr LLC - MarketBeat
HC Wainwright & Co. Initiates Coverage of Bicara Therapeutics (BCAX) with Buy Recommendation - MSN
Maven Securities LTD Buys Shares of 50,000 Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
35,000 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Acquired by Samsara BioCapital LLC - MarketBeat
RA Capital Management L.P. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Point72 DIFC Ltd Takes $1.42 Million Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Baker BROS. Advisors LP Makes New $21.23 Million Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Braidwell LP Makes New $42.22 Million Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Vestal Point Capital LP Acquires Shares of 425,000 Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
First Turn Management LLC Takes $14.32 Million Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
FY2024 EPS Estimates for BCAX Cut by Cantor Fitzgerald - Defense World
FY2024 EPS Estimates for BCAX Reduced by Cantor Fitzgerald - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 6.2%Here's Why - MarketBeat
Bicara Therapeutics Reports Strong IPO and Clinical Advancements - TipRanks
Bicara Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Bicara Therapeutics: Newly Minted Upsized IPO With Positive Early Data (NASDAQ:BCAX) - Seeking Alpha
Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Bicara's $362M IPO Success Powers Cancer Drug Trial with 64% Response Rate | BCAX Stock News - StockTitan
Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference - The Manila Times
Bicara Therapeutics (NASDAQ:BCAX) Rating Increased to Strong-Buy at RODMAN&RENSHAW - Defense World
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $43.33 Consensus Target Price from Analysts - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Upgraded to "Strong-Buy" at RODMAN&RENSHAW - MarketBeat
Bicara Therapeutics stock gets Buy rating from H.C. Wainwright on asset - Investing.com
Rodman & Renshaw Begins Coverage on Bicara Therapeutics (NASDAQ:BCAX) - MarketBeat
Biocon Stole Licensed Cancer Biotech to Fuel Spinoff, Suit Says - Bloomberg Law
Morgan Stanley spotlights 10 small-cap stocks with at least 50% upside - Kursiv Media
Bicara Therapeutics (NASDAQ:BCAX) Trading Up 7.9%Should You Buy? - MarketBeat
Balance Sheet Breakdown: Bicara Therapeutics Inc. (BCAX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
In the Green: Bicara Therapeutics Inc. (BCAX) Closes at 19.00, Up/Down -6.40 from Previous Day - The Dwinnex
Bicara Therapeutics (NASDAQ:BCAX) Hits New 52-Week LowWhat's Next? - MarketBeat
Down rounds don’t aid post-IPO performance - BioCentury
Bicara shares initiated with Buy on cancer drug potential By Investing.com - Investing.com South Africa
Bicara stock poised for growth with late-stage transition, Morgan Stanley optimistic - Investing.com
Bicara Therapeutics stock sees upside with lead drug potential, says Stifel - Investing.com
Bicara shares initiated with Buy on cancer drug potential - Investing.com India
Cantor Fitzgerald starts Bicara Therapeutics with Overweight rating - Investing.com
Cantor Fitzgerald starts Bicara Therapeutics with Overweight rating By Investing.com - Investing.com South Africa
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):